Organon
Organon & Co., a global healthcare company headquartered in the United States, focuses on women's health, biosimilars, and other critical therapeutic areas. Founded in 2021, Organon emerged as a spin-off from Merck & Co., marking a significant milestone in the pharmaceutical industry. The company is dedicated to addressing unmet medical needs through innovative products and services, particularly in reproductive health and chronic conditions. With a robust portfolio that includes contraceptives, hormone therapies, and biosimilars, Organon distinguishes itself by prioritising women's health and empowering patients. The company has quickly established a strong market position, recognised for its commitment to improving health outcomes and enhancing access to essential medications. As it continues to expand its global footprint, Organon remains focused on delivering impactful solutions that resonate with healthcare providers and patients alike.
DitchCarbon Score
How does Organon's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Organon's score of 43 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Organon's reported carbon emissions
In 2023, Organon reported total carbon emissions of approximately 7,000,000 kg CO2e, comprising 2,272,000 kg CO2e from Scope 1 and 5,557,000 kg CO2e from Scope 2 emissions. Additionally, Scope 3 emissions were significant, with business travel contributing 415,000 kg CO2e, employee commute at 830,000 kg CO2e, waste generated in operations at 130,000 kg CO2e, and both upstream and downstream transportation and distribution each at 920,000 kg CO2e. Organon has set ambitious targets to reduce its Scope 1 and 2 greenhouse gas emissions by more than 25% from 2020 levels by 2025. This commitment reflects a proactive approach to climate action, aiming to enhance sustainability within its operations. The company’s emissions data is not cascaded from any parent organization, indicating that these figures are independently reported. In 2022, Organon’s emissions were approximately 6,000,000 kg CO2e, showing a slight increase from 2021, where emissions were around 32,014,000 kg CO2e for Scope 1 and 31,842,000 kg CO2e for Scope 2. The company continues to focus on reducing its carbon footprint while maintaining operational efficiency, aligning with industry standards for climate responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 30,521,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 32,908,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Organon is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
